Nemera: Drug delivery devices

Nemera breaks ground in Brazil through Milfra acquisition
With this acquisition Nemera establishes an operational footprint in Brazil and expands its product and services offering to better serve the pharmaceutical industry in Latin America.
Read the press release
Nemera’s preservative-free multi-dose eyedropper approved in Brazil for Aché’s NSAID’s and Dry Eye formulations
Nemera is excited to announce that its multidose eye dropper Novelia® has been approved by ANVISA for Aché’s preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.
Find out more!
Nemera is attending RDD digital show 2021
In an on-demand presentation, our ear,nose and throat experts - Pascale Farjas and Alain Regard will discuss the “Key success factors for bioequivalence nasal spray development”. A live Q&A will then follow on Thursday May 6th at 5:15 pm (CEST). We look forward to seeing you there.
Know more!

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries

We leverage a long standing experience to provide you leading-edge drug delivery devices
for different application areas, from design to large scale manufacturing.

Device design & development

World Class Innovation Center: we are passionate to develop the best solutions
Learn more

100% quality focused manufacturing

Global GMP manufacturing capabilities and strong continuous improvement culture
Learn more

A wide range of drug delivery devices for every application

Ophthalmic Preservative-free multidose eye dropper
Ophthalmic
Nasal spray bioequivalence
Ear, Nose, Throat
Passive safety system for prefilled syringes
Parenteral
Airless dispenser for dermal topical delivery
Dermal
Inhaler for astham and COPD
Inhalation

Our latest news

Contact us

E-mail: [email protected]

This form collects your name and email so that we can send you your requested content. Check out our legal notices for more details.

Linkedin-in Twitter Youtube